Connect with us

BUSINESS

Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) Mobilizes Funds to Advance Cannabinoid-based Drug Delivery Production

Published

on

Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) has mobilized $500,000 to expedite cannabinoid drug delivery production. The company has received a convertible loan from a strategic partner.

Chief Executive Officer of Cure Pharmaceutical, Rob Davidson funding is vital for advancing the cannabinoid program. The therapies developed using CBD will help to cure a number of disease indications. The main aim of the company is to accelerate cannabinoid drug delivery treatment with the help of CUREfilm.

The chemical compounds – cannabinoids are sourced from cannabis plants. CBD interacts with endocannabinoid system of humans. It is used for the treatment of indications like inflammation, anxiety, nausea, pain and central nervous system disorders.

Rob Davidson Gives a Presentation On Increasing Bioavailability of Cannabinoid Molecules Using Proprietary Technologies

Rob Davidson will give a presentation on increasing bioavailability of the cannabinoid molecules with the help of proprietary delivery technologies at the O’Cannabiz Conference & Expo on June 9, 2018, in Toronto Canada.

The bioavailability of cannabinoids is very low and only a fraction of that will be absorbed in the blood when ingested. The medications will be more effective with the help of innovative drug delivery technologies including CUREfilm.

Davidson will explain how the drug delivery technologies such as nasal, transdermal, and oral options help to increase the bioavailability of cannabinoid molecules. He will also provide more details about research on cannabinoid molecules intended for the treatment of sleep disorders.

Cure Pharmaceutical Holding Corp Gets Two Patents for the Extraction/ Purification of Bioactive Cannabinoid Molecules

Cure Pharmaceutical Holding Corp has secured two patents to maintain an upper hand in the extraction/ purification of cannabis.

Brief Information about Cure Pharmaceutical Holding Corp

The vertically integrated drug development and delivery company Cure Pharmaceutical is committed to enhancing drug safety, efficacy and patient experience with the help of its drug dosage forms. It has proprietary and patented delivery system – CUREfilm.

CURE is developing a number of products in latest delivery platforms. It is also entering into partnerships with firms in the US, Germany, Israel, and Canada to expedite therapeutic categories. The company is committed to improving the lives of people by redefining the delivery of medicines.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

Aleafia Health Inc (OTCMKTS: ALEAF) Appoints David Pasieka to Board of Directors, and Stereo Vision Entertainment Inc (OTCMKTS: SVSN) Has David Waite as Independent Director

Published

on

Aleafia Health Inc (OTCMKTS: ALEAF) announced that the group had appointed David Pasieka to its board of directors. Meanwhile, the group also announced the departure of director Mike LeClair. It is learned that Pasieka has credit experience in finance, audit, risk management, and ESG. Before this new appointment, Pasieka has taken the position of an entrepreneur in residence at the MaRS Discovery District.  

Pasieka will serve both management and the board

On behalf of Aleafia Health Inc, Mark J. Sandler, chair of the company’s board of directors, wished the outgoing director LeClair good luck in his future endeavors. In addition, Sandler welcomed Pasieka and expressed that Pasieka holds a professional track record as a leader who aims to take the business to the next level of growth and help serve the board and the management of the group. The chair of the company’s board of directors is confident that the team will strengthen the group’s position in medical and commercial markets. 

Aleafia Health Inc is a licensed Canadian cannabis company that offers a range of cannabis health and wellness services and products in Canada. In addition, the group has a presence in the international market. 

Stereo Vision Entertainment Inc (OTCMKTS: SVSN) announces David Waite as Independent Director

Stereo Vision Entertainment Inc (OTCMKTS: SVSN) conveyed that its board of directors has unanimously elected David Waite as Independent Director. In addition, Waite of Waite Enterprises LLC is appointed on the StereoVisions Board of Directors for Stereovisions planned uplisting to the OTCQB, it is learned.

CEO of the group Jack Honour welcomed Waite as Independent Director to StereoVisions Board and added that Waite has his credit experience in sales consulting. It is also learned that Waite has donned many hats before taking up the new responsibility assigned to him. He has served as a consultant for state and federal government agencies in sectors including banking, industry, and financial services. Stereo Vision Entertainment Inc is a Nevada publicly traded company. 

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

INDVR Brands Inc. (OTCMKTS: CAAOF) Appoints Chairman and CEO, and Hexo Corp (NASDAQ: HEXO) Has New Chief People and Culture Officer

Published

on

INDVR Brands Inc. (OTCMKTS: CAAOF) is back in the news. The group, in a statement, announced that Hugh Hempel would play the role of Chairman and CEO with immediate effect. In addition, the group made it official that Joshua Mann, the former CEO, will continue to serve as a non-executive member of the board of directors. It has also come to light that Mann will work with Hempel on asset integrations, and the duo will take the company to the next stage. 

The duo will work on enhancing the product portfolio of the group

The former CEO of the company stated that he is looking ahead to working with Hempel to strengthen the company’s product portfolio. Mann added that INDVR Brands Inc. has built a strong foundation with its existing range of products and added that the company is all set to scale to the next level of growth. In addition, the team is confident of the wealth of experience their leader brings with him in the sector, as Hempel is regarded as one of the pioneers in the U.S. Cannabis industry. 

INDVR Brands Inc. aims at expanding its famous hemp and cannabis brands throughout North America. The company has a portfolio of award-winning products which have many takers. 

Hexo Corp (NASDAQ: HEXO) appoints Chief People and Culture Officer

Hexo Corp (NASDAQ: HEXO), in a statement, announced that Guillaume Jouët would serve as Chief People and Culture Officer. The appointment is effective from September 8 2021.  Sebastien St-Louis, CEO, and co-founder, Hexo Corp, said that the workforce is the biggest asset for the company.

The CEO added that the group is happy to have Jouët on board when the company is working on strategies to expand in Canada and spread its wings across the U.S. and globally. In the backdrop of this, Jouët, who is regarded as a vital member of the team, will work on areas like public affairs, communications functions, and human resources. In addition, the group appointed Valerie Malone as its Chief Commercial Officer earlier this month. Malone will work closely with the organization’s marketing, sales, and product development groups and will be responsible for commercial strategy and development.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Vext Science Inc (OTCMKTS: VEXTF) Declares Record 2Q 2021 Results With Revenue of $9.4 Million

Published

on

Vext Science Inc (OTCMKTS: VEXTF) recently announced its financial results for 2Q 2021. The group reported a record revenue of $9.4 million. Throwing light on other numbers, the company announced adjusted EBITDA of $3.4 million, fully diluted EPS stands at $0.01 while the operating cash flow is $4.5 million. These are the record financial results of the group. 

CEO comments that consistent efforts delivered record results

Crediting the team at Arizona for their outstanding performance at the dispensary level, Eric Offenberger, CEO of Vext Science Inc, stated that the persistent demand for the Vapen brand from third-party dispensaries from across the state contributed to a spike in sales. The effort has resulted in helping the company earn profit besides increasing the operating cash flow. In terms of numbers, expectations are pinned high on the Arizona market as it is expected to generate $3 billion in annual sales by 2025. Against this backdrop, the CEO informed that the company positioned itself to achieve the targeted sales number. 

Alongside registering profit through an increase in sales, the group is also expanding its manufacturing capability. The CEO announced that the company sealed a purchase deal of a 72,000 square foot facility, reportedly located in Eloy. When this comes online in early 2022, as expected, the indoor cultivation capacity of the group will nearly triple. 

Commenting on another milestone achieved in Arizona, Offenberger informed that Vext Science Inc agreed to produce and distribute MAJOR cannabis-infused beverages and Wynk THC seltzers in Arizona in July. Moving the focus away from Arizona, the CEO informed that the group had made remarkable progress in Ohio, as the Vapen brand has many takers in the market. Expectations are pinned high in both regions. The corporate house expects growth in the following 12 months, and this period is also a time when the company is hoping to expand its presence in many states. 

Other milestones achieved by Vext Science Inc

The group announced that it has entered into a Memorandum of Understanding (MoU) with SōRSE Technology Corp. to exclusively produce and sell SōRSE’s MAJOR cannabis-infused beverages in Arizona. In July this year, the corporate house announced that it would establish its retail presence in Ohio. In the same month, the US-based Cannabis THC manufacturing company announced that it had joined hands with Agtech PA LLC. In Arizona, the partnership allows Vext Science Inc to exclusively produce and sell Wynk THC seltzers (“Wynk”).

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories